[Induction of malignant neoplasm].
Anti -rheumatic drugs are classified to immunosuppressive drugs/immunisation adjustment drugs/biological drugs. The induction of malignant neoplasm by biological drugs having tumor necrosis factor (TNF) inhibitory action has been concerned about, and various epidemiological studies have been done. It has been shown that methotrexate could induce a malignant lymphoma in patients with rheumatoid arthritis at time. With regard to malignant neoplasm induction by biological drugs, there are some reports to suggest the risk, but there are many problems about accuracy of statistics. In this paper, epidemiological analyses which refer to the risk of complications or induction of malignant neoplasm by methotrexate and biological drugs in patients with rheumatoid arthritis, has been reviewed.
Tohma
Shigeto
S
Clinical Research Center for Allergy and Rheumatology, National Hospital Organization, Sagamihara National Hospital.
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D000069285:Infliximab; D008223:Lymphoma / Q000453:epidemiology / Q000209:etiology; D008727:Methotrexate / Q000009:adverse effects*; D009369:Neoplasms / Q000453:epidemiology / Q000209:etiology*; D018124:Receptors, Tumor Necrosis Factor; D012306:Risk; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000502:physiology
D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept; D008727:Methotrexate